MedaSorb Technologies Corporation
7 Deer Park Drive
Suite K
Monmouth Junction,
NJ 08852
United States - Map
Phone: 732-329-8885
Fax: 732-329-8650
Web Site: http://www.medasorb.com
| Medasorb Technologies Corporation, a development stage medical device company, focuses on developing and commercializing blood purification technologies that would remove middle molecular weight toxins from circulating blood and physiologic fluids. Its products include CytoSorb device, which is intended to remove toxins and other substances from blood and physiologic fluids, as well as for adjunctive therapy applications in the treatment of sepsis; the prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and the prevention and treatment of post-operative complications of cardiopulmonary bypass surgery. The companys products also comprise BetaSorb device that utilizes an adsorbent polymer packed into a cartridge and incorporates connectors at either end of the device to connect directly into the extra-corporeal circuit in series with a dialyzer. Its BetaSorb is intended to remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure, who rely on long term dialysis therapy to sustain their life, as well as for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure. The company was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Phillip Chan M.D., Ph.D., 39
Chief Exec. Officer, Pres, Director and Member of Compensation Committee |
$
4.00K | N/A | Mr. Joseph Rubin Esq., 71
Founder |
$
8.00K | N/A | Mr. David Lamadrid , 38
Chief Financial Officer, Principal Accounting Officer and Sec. |
$
157.00K | N/A | Mr. Vincent Capponi , 51
Chief Operating Officer |
$
195.00K | N/A | Dr. Robert Bartlett MD, 69
Chief Medical Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.29% Nasdaq 
Profile
